Artigos com autorizações de acesso público - Paul KwoSaiba mais
8 artigos não disponíveis publicamente
Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation: analysis of risk factors and outcomes for portal vein thrombosis in waitlisted patients
M Ghabril, S Agarwal, M Lacerda, N Chalasani, P Kwo, AJ Tector
Transplantation 100 (1), 126-133, 2016
Autorizações: US National Institutes of Health
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
C Hézode, GM Hirschfield, W Ghesquiere, W Sievert, M Rodriguez-Torres, ...
Gut 64 (6), 948-956, 2015
Autorizações: US National Institutes of Health
Short‐duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOUR ward study)
MS Sulkowski, S Flamm, Z Kayali, EJ Lawitz, P Kwo, F McPhee, ...
Liver International 37 (6), 836-842, 2017
Autorizações: US National Institutes of Health
Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study
K Berman, S Tandra, R Vuppalanch, M Ghabril, K Sandrasegaran, ...
Official journal of the American College of Gastroenterology| ACG 106 (5 …, 2011
Autorizações: US National Institutes of Health
Overall safety profile of boceprevir plus peginterferon alfa‐2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
MP Manns, J McCone Jr, MN Davis, L Rossaro, E Schiff, ML Shiffman, ...
Liver International 34 (5), 707-719, 2014
Autorizações: US National Institutes of Health
Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis‐related hospitalisations in the US
AK Singal, YF Kuo, KR Reddy, R Bataller, P Kwo
Alimentary Pharmacology & Therapeutics 56 (10), 1486-1496, 2022
Autorizações: US National Institutes of Health
Impact of advanced practice providers on characteristics and quality of care of patients with chronic hepatitis B
LY Kam, DQ Huang, AF Tobias, K Poon, L Henry, P Kwo, R Cheung, ...
Alimentary Pharmacology & Therapeutics 56 (11-12), 1591-1601, 2022
Autorizações: US National Institutes of Health
Hepatitis C Screening in Post–Baby Boomer Generation Americans: One Size Does Not Fit All
P Sripongpun, P Udompap, A Mannalithara, NL Downing, AA Vidovszky, ...
Mayo Clinic Proceedings 98 (9), 1335-1344, 2023
Autorizações: American Heart Association
31 artigos disponíveis publicamente
Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease
M Charlton, GT Everson, SL Flamm, P Kumar, C Landis, RS Brown Jr, ...
Gastroenterology 149 (3), 649-659, 2015
Autorizações: US National Institutes of Health
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis
NC Boetticher, CJ Peine, P Kwo, GA Abrams, T Patel, B Aqel, L Boardman, ...
Gastroenterology 135 (6), 1953-1960, 2008
Autorizações: US National Institutes of Health
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1
KV Kowdley, E Lawitz, F Poordad, DE Cohen, DR Nelson, S Zeuzem, ...
New England Journal of Medicine 370 (3), 222-232, 2014
Autorizações: US National Institutes of Health
Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study
D Kim, N Adeniji, N Latt, S Kumar, PP Bloom, ES Aby, P Perumalswami, ...
Clinical Gastroenterology and Hepatology 19 (7), 1469-1479. e19, 2021
Autorizações: US National Institutes of Health
Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection
MS Sulkowski, HE Vargas, AM Di Bisceglie, A Kuo, KR Reddy, JK Lim, ...
Gastroenterology 150 (2), 419-429, 2016
Autorizações: US National Institutes of Health
Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease
K Berman, S Tandra, K Forssell, R Vuppalanchi, JR Burton Jr, J Nguyen, ...
Clinical Gastroenterology and Hepatology 9 (3), 254-259, 2011
Autorizações: US National Institutes of Health
Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors
AJ Kwong, A Wall, M Melcher, U Wang, A Ahmed, A Subramanian, ...
American Journal of Transplantation 19 (5), 1380-1387, 2019
Autorizações: US National Institutes of Health
Interferon‐free therapy for genotype 1 hepatitis C in liver transplant recipients: Real‐world experience from the hepatitis C therapeutic registry and research network
RS Brown Jr, JG O'Leary, KR Reddy, A Kuo, GJ Morelli, JR Burton Jr, ...
Liver Transplantation 22 (1), 24-33, 2016
Autorizações: US National Institutes of Health
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection—a randomized trial
F Poordad, E Lawitz, KR Reddy, NH Afdhal, C Hézode, S Zeuzem, ...
Gastroenterology 145 (5), 1035-1044. e5, 2013
Autorizações: US National Institutes of Health
All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database
KR Reddy, JK Lim, A Kuo, AM Di Bisceglie, JS Galati, G Morelli, ...
Alimentary pharmacology & therapeutics 45 (1), 115-126, 2017
Autorizações: US National Institutes of Health
De novo malignancy post–liver transplantation: a single center, population controlled study
H Chatrath, K Berman, R Vuppalanchi, J Slaven, P Kwo, AJ Tector, ...
Clinical transplantation 27 (4), 582-590, 2013
Autorizações: US National Institutes of Health
Interleukin 28B polymorphisms are the only common genetic variants associated with low‐density lipoprotein cholesterol (LDL‐C) in genotype‐1 chronic hepatitis C and determine …
PJ Clark, AJ Thompson, M Zhu, DM Vock, Q Zhu, D Ge, K Patel, ...
Journal of viral hepatitis 19 (5), 332-340, 2012
Autorizações: US National Institutes of Health
As informações de publicação e financiamento são determinadas automaticamente por um programa de computador